Download The Findit App

Share Your Posts On These Major Social Networks

Instatag Your Posts to Instagram Facebook + Twitter

News

Aikido Pharma Establishes Licensing Agreement with University of Maryland
for Antiviral Compounds, Including COVID-19

New York 2/10/2021 6:49:00 PM

Aikido Pharma Inc, biotechnology development company working to develop a diverse portfolio of early and mid-stage small-molecule anti-cancer therapeutics, has established a licensing agreement with the University of Maryland for Antiviral Compounds, including COVID-19.

On April 14, 2020, the Company announced that it has secured an exclusive world-wide license for a broad spectrum antiviral drug platform. The licensed technology is a broadly acting pan-viral inhibitory compound with efficacy against multiple viral pathogens. The technology works to inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

About Aikido Pharma Inc
AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics. The Spherix platform contains patented technology from leading universities and researchers and we seek to develop our innovative drugs through strong partnership with world renowned institutions, such as The University of Texas and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). Our pancreatic treatment has shown positive preclinical results for inhibiting pancreatic tumor growth in clinically relevant transgenic mouse models.

The drug has also demonstrated the potential to overcome tumor cell resistance to current chemotherapeutic drugs. Our AML drug is a next generation targeted therapeutic designed to overcome multiple resistance mechanisms observed with the current standard of care. In addition, we are constantly seeking to grow our pipe to treat unmet medical needs in oncology.

More News

https://s3.amazonaws.com/findit-pictures/351133/5a9367a7-1d67-477a-8321-e8a4173d690f.jpg

Aikido Pharma Has Licensed DHA-dFdC at The University of Texas at Austin

Aikido Pharma Has Licensed DHA-dFdC at The University of Texas at Austin

Released On: 3/5/2021
Views: 447

https://s3.amazonaws.com/findit-pictures/351133/b9cc6d12-45b2-42d8-98c3-1ea2961eecad.jpg

Aikido Pharma Shares Published Papers and Articles on KPC-34 and DHA-dFdC

Aikido Pharma Shares Published Papers and Articles on KPC-34 and DHA-dFdC

Released On: 3/3/2021
Views: 430

https://s3.amazonaws.com/findit-pictures/351133/86c80767-4bb8-48ba-b5be-f5c6e1ff2d4d.jpg

Aikido Pharma Announces Findings of Positive Results From New Drug “DHA-dFdC” Developed at The University of Texas at Austin

Aikido Pharma Announces Findings of Positive Results From New Drug “DHA-dFdC” Developed at The University of Texas at Austin

Released On: 3/1/2021
Views: 445

https://s3.amazonaws.com/findit-pictures/351133/d1155add-3bd8-4751-8661-f9c48c2f069d.jpg

AIkido Pharma Inc. to Present at the H.C. Wainwright Global Life Sciences Conference (Virtual Event)

AIkido Pharma Inc. to Present at the H.C. Wainwright Global Life Sciences Conference (Virtual Event)

Released On: 3/1/2021
Views: 789

https://s3.amazonaws.com/findit-pictures/351133/48a25696-dac4-4e6d-bc52-6d181debb131.jpg

Meet Aikido Pharma Inc’s Board of Directors

Meet Aikido Pharma Inc’s Board of Directors

Released On: 2/28/2021
Views: 464

https://s3.amazonaws.com/findit-pictures/351133/06f2c09a-2436-4e6b-8eb3-f07578c8ab17.jpg

AIkido Pharma Inc. Announces Exercise of Option to Purchase Additional Shares in Bought Deal Offering

AIkido Pharma Inc. Announces Exercise of Option to Purchase Additional Shares in Bought Deal Offering

Released On: 2/23/2021
Views: 514

https://s3.amazonaws.com/findit-pictures/351133/bf0df713-8e2e-44ac-9609-f12bdf9847eb.jpg

Artificial Intelligence Is Optimizing Drug Development

Artificial Intelligence Is Optimizing Drug Development

Released On: 2/22/2021
Views: 523

https://s3.amazonaws.com/findit-pictures/351133/fad82173-54eb-4dcf-b365-5cf437598e16.jpg

Aikido Pharma Focuses on The Treatment of Four Main Types of Cancer

Aikido Pharma Focuses on The Treatment of Four Main Types of Cancer

Released On: 2/20/2021
Views: 416

https://s3.amazonaws.com/findit-pictures/351133/f5052f01-a9c3-48cf-8558-12b7f8dd5d85.jpg

AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock

AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock

Released On: 2/19/2021
Views: 571

https://s3.amazonaws.com/findit-pictures/351133/9642dc86-4305-4113-a789-78af0ea01972.jpg

AIkido Pharma Inc. Increases Previously Announced Bought Deal Offering of Common Stock to $75 Million

AIkido Pharma Inc. Increases Previously Announced Bought Deal Offering of Common Stock to $75 Million

Released On: 2/16/2021
Views: 657

https://s3.amazonaws.com/findit-pictures/351133/d64287af-b96d-47bb-a32b-65ddb76ff3d4.jpg

AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock

AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock

Released On: 2/16/2021
Views: 597

https://s3.amazonaws.com/findit-pictures/351133/54fa1d0c-edd2-4000-b922-08b0837dba1a.jpg

AIkido Pharma Enters Into Letter Of Intent With Silo Pharma for Use of Psilocybin and Peptide Therapy for Cancer Treatment

AIkido Pharma Enters Into Letter Of Intent With Silo Pharma for Use of Psilocybin and Peptide Therapy for Cancer Treatment

Released On: 2/16/2021
Views: 655

https://s3.amazonaws.com/findit-pictures/351133/d6d4252d-f996-436f-bf91-6c83af43e756.jpg

Aikido Pharma Announces Information on KPC-34 Which Was Developed at the Wake Forest School of Medicine

Aikido Pharma Announces Information on KPC-34 Which Was Developed at the Wake Forest School of Medicine

Released On: 2/15/2021
Views: 424

https://s3.amazonaws.com/findit-pictures/351133/8ac95bfe-f94b-4b9f-b39a-98d7aa7f6abd.jpg

Aikido Pharma Establishes Licensing Agreement with University of Maryland
for Antiviral Compounds, Including COVID-19

Aikido Pharma Establishes Licensing Agreement with University of Maryland
for Antiviral Compounds, Including COVID-19

Released On: 2/10/2021
Views: 343

https://s3.amazonaws.com/findit-pictures/351133/cdbebd8e-c86d-4537-8940-1b1b2ea0b06e.jpg

Aikido Pharma Announces DHA-dFdC Which Is Licensed From the University of Texas at Austin for the treatment of Pancreatic Cancer.

Aikido Pharma Announces DHA-dFdC Which Is Licensed From the University of Texas at Austin for the treatment of Pancreatic Cancer.

Released On: 2/9/2021
Views: 814

https://s3.amazonaws.com/findit-pictures/351133/09f4b098-397e-40d6-8af9-bacf930bb0cf.jpg

Aikido Pharma Secures Early Interest in Convergent Therapeutics, Inc. Who Focuses On Next Generation Radiopharmaceutical Therapy for Prostate Cancer

Aikido Pharma Secures Early Interest in Convergent Therapeutics, Inc. Who Focuses On Next Generation Radiopharmaceutical Therapy for Prostate Cancer

Released On: 2/5/2021
Views: 455

https://s3.amazonaws.com/findit-pictures/351133/59ca97a6-b0e3-47f3-adef-57939fddd0e5.jpg

AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board

AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board

Released On: 2/3/2021
Views: 1061

https://s3.amazonaws.com/findit-pictures/351133/e6e1220e-0686-4d01-8029-a87b9d54e412.jpg

Meet Aikido Pharma A BioTechnology Development Company Focused on The Treatment Of Early and Mid-Stage Small-Molecule Anti-Cancer Therapeutics

Meet Aikido Pharma A BioTechnology Development Company Focused on The Treatment Of Early and Mid-Stage Small-Molecule Anti-Cancer Therapeutics

Released On: 2/3/2021
Views: 537

Load More wait

Map

Aikido Pharma

Get Directions

Aikido Pharma

  • One Rockefeller Plaza
    New York, New York 10020
    United States
  • (212) 745-1373